NASDAQ: OACCOaktree Acquisition Corp III Life Sciences Stock
$10.65+0.00 (+0%)
Updated Jun 18, 2026
OACC Price
$10.65
Fair Value Price
N/A
Market Cap
$261.81M
52 Week Low
$10.30
52 Week High
$10.74
P/E
35.5x
P/B
-36.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$7.02M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.2
Operating Cash Flow
-$505k
Beta
0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OACC Overview
Oaktree Acquisition Corp. III Life Sciences is dedicated to completing a strategic business combination, such as a merger, asset acquisition, share purchase, reorganization, or similar transaction, with one or more companies. The firm's focus is on identifying and acquiring entities within the biopharmaceutical, medical device, diagnostics, and specialized healthcare services industries located across North America and Europe. This company was formed in 2024 and is headquartered in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OACC's potential to beat the market
- OACC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Shell Company
Industry Rating
F
OACC
RankedUnranked of 30
RankedUnranked of 30
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.80 | C | |
| $11.14 | C | |
| $12.57 | C |
Be the first to know about important OACC news, forecast changes, insider trades & much more!
OACC News
Overview
Due Diligence Score
–
Industry Average (6)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OACC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OACC is poor value based on its earnings relative to its share price (35.5x), compared to the US market average (9.47x)
P/E vs Market Valuation
OACC is poor value based on its earnings relative to its share price (35.5x), compared to the US Shell Companies industry average (15.56x)
P/E vs Industry Valuation
OACC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OACC due diligence checks available for Premium users.
Valuation
OACC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
35.5x
Industry
15.56x
Market
9.47x
OACC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
OACC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
OACC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-36.23x
Industry
78.32x
OACC's financial health
Profit margin
Revenue
$0.0
Net Income
$1.4M
Profit Margin
0%
OACC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$204.8M
Liabilities
$8.6M
Debt to equity
-1.2
OACC's short-term liabilities ($1.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OACC's long-term liabilities ($7.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OACC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OACC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$158.0k
Investing
$0.0
Financing
$0.0
OACC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OACC vs Shell Company Stocks
Oaktree Acquisition III Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.